Search PubMed⌕ Search
Home/Archive/PubMed

PubMed · 12728514

Interdisciplinary collaboration: the obvious need and basic structures.

Sarah Riegelhaupt·Uriel Halbreich
View original source ↗Export metadata ↓

Abstract

In the last decade there has been an exponential increase in knowledge in the field of medicine in general and particularly in Neurosciences. In order for the continuation of progress, it is important for professionals in all fields to collaborate with each other. Interdisciplinary collaboration is an absolute must to be able to obtain new knowledge, quickly and efficiently. Another important aspect is for professionals to collaborate with industry--especially the pharmaceutical industry. The global pharmaceutical companies account for a large amount of resources including personnel, knowledge, and especially funds. Although interdisciplinary collaboration is essential, many times potential partners overlook the obvious need for their own personal ongoing politics. Such competition needs to be overcome and new fields with multiple perspectives from different specialties will lead the way through the new millennium.

Explore related subjects

Drug DesignDrug IndustryHumansInterdisciplinary CommunicationMedicineNeurosciencesLecture

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

Sarah Riegelhaupt, Uriel Halbreich. 2003. Interdisciplinary collaboration: the obvious need and basic structures.. https://pubmed.ncbi.nlm.nih.gov/12728514/

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related citations

PubMed2003

Design, synthesis and biological evaluation of 10-CF3CO-DDACTHF analogues and derivatives as inhibitors of GAR Tfase and the de novo purine biosynthetic pathway.

The synthesis and evaluation of analogues and key derivatives of 10-CF3CO-DDACTHF as inhibitors of glycinamide ribonucleotide transformylase (GAR Tfase) and aminoimidazole carboxamide transformylase (AICAR Tfase) are reported. Polyglutamate analogues of 1 were evaluated as inhibitors of Escherichia coli and recombinant human (rh) GAR Tfase, and AICAR Tfase. Although the pentaglutamate 6 was found to be the most active inhibitor of the series tested against rhGAR Tfase (Ki=0.004 microM), little distinction between the mono-pentaglutamate derivatives was observed (Ki=0.02-0.004 microM), suggesting that the principal role of the required polyglutamation of 1 is intracellular retention. In contrast, 1 and its defined polyglutamates 3-6 were much less inactive when tested against rhAICAR Tfase (Ki=65-0.120 microM) and very selective (> or =100-fold) for rh versus E. coli GAR Tfase. Additional key analogues of 1 were examined (7 and 8) and found to be much less active (1000-fold) highlighting the exceptional characteristics of 1.

Drug Design↗
PubMed2003

An ultra-HTS process for the identification of small molecule modulators of orphan G-protein-coupled receptors.

G-protein-coupled receptors (GPCRs) are the most successful target proteins for drug discovery research to date. More than 150 orphan GPCRs of potential therapeutic interest have been identified for which no activating ligands or biological functions are known. One of the greatest challenges in the pharmaceutical industry is to link these orphan GPCRs with human diseases. Highly automated parallel approaches that integrate ultra-high throughput and focused screening can be used to identify small molecule modulators of orphan GPCRs. These small molecules can then be employed as pharmacological tools to explore the function of orphan receptors in models of human disease. In this review, we describe methods that utilize powerful ultra-high-throughput screening technologies to identify surrogate ligands of orphan GPCRs.

Drug Design↗